Experimental lung cancer drug trial halted early – only 18 patients enrolled

NCT ID NCT05765734

Terminated Disease control Sponsor: Taiho Oncology, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested a new drug, TAS3351, in 18 people with advanced lung cancer that had a specific genetic change (EGFR mutation). The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early, so results are limited.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Institut Gustave Roussy

Villejuif, Val De Marne, 94805, France
Leiden University Medical Center (LUMC)

Leiden, 2333ZA, Netherlands
National Cancer Center Hospital East

Kashiwa-shi, Chiba, 277-8577, Japan
Next Oncology - Virginia

Fairfax, Virginia, 22031, United States
Shizuoka Cancer Center

Sunto-gun, Shizuoka, 411-8777, Japan
Tennessee Oncology

Nashville, Tennessee, 37203, United States
Universitaetsklinikum Koeln

Cologne, North Rhine-Westphalia, 50937, Germany
University of Texas M. D. Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.